Type:
Educational Exhibit
Keywords:
Oncology, CT, MR, PET-CT, Complications, Cancer, Drugs / Reactions, Monoclonal antibodies
Authors:
E. A. Rincon, M. Renjifo, H. J. Delgado Argote, E. J. Ortiz Hormaza; Cali/CO
DOI:
10.26044/ecr2021/C-12779
Background
Currently, there are more than 85 target therapies against up to 27 types of cancer. These therapies attack signaling pathways important for proliferation and survival of cancer cells or activate immune checkpoints and thus stimulate antitumor immune response.
Adverse effects can be expected in a frequency as high as 90%. A deep understanding of its molecular basis allows us to explain their radiological findings in order to identify them promptly and differentiate them from other relevant entities that require specific treatments, including tumor progression.
Radiologists must be able to promptly identify and follow up different toxicities associated with these drugs to have an active role in the multidisciplinary care of cancer patients and effective communication with treating oncologist.